Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the recipient of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 50,407 shares, a growth of 327.4% from the May 14th total of 11,793 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 359,949 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Chugai Pharmaceutical has an average rating of “Buy”.

Chugai Pharmaceutical Stock Down 0.7%

OTCMKTS:CHGCY traded down $0.16 during mid-day trading on Friday, hitting $23.37. 159,906 shares of the stock traded hands, compared to its average volume of 235,948. The business’s 50-day moving average price is $25.73 and its 200 day moving average price is $27.21. The company has a market cap of $76.92 billion, a PE ratio of 25.97 and a beta of 0.58. Chugai Pharmaceutical has a 12-month low of $19.50 and a 12-month high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, April 24th. The company reported $0.22 EPS for the quarter. The company had revenue of $2.05 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. Analysts anticipate that Chugai Pharmaceutical will post 0.98 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.